



**LETTER OF ANNOUNCEMENT
EMVO NOTICE TO FUTURE ON-BOARDING PARTNERS**

Thursday, the 15th of February 2018

Dear Future On-boarding Partner,

We are writing you on behalf of the European Medicines Verification Organisation (EMVO). The purpose of this letter is to provide you with information and guidance concerning your On-boarding to the European Medicines Verification System.

The risk of falsified medicines is growing on a global scale. As a result, the European Commission published on the 1st of July 2011 the Falsified Medicines Directive (Directive 2011/62/EU), introducing tougher rules to prevent falsified medicines from entering the legal supply chain. The Directive is supplemented by a Delegated Regulation (2016/161 DR), as published on the 9th of February 2016, which details the characteristics of the safety features, how the medicines authenticity should be verified, and by whom within the pharmaceutical supply chain.

EMVO undertakes all necessary actions to set up the European Medicines Verification System on time and to ensure that the system will be compliant with the FMD provisions. More than 2000 pharmaceutical companies have to connect their IT System to the EU Hub and start the On-boarding Process to be compliant with Directive 2011/62/EU. So far, only 500 of them has started the On-boarding Process.

In case your company hasn't started the On-boarding Process yet, please consult the following information material, and initiate the process as soon as possible:

- [Detailed information](#) on which company will be the EMVO On-boarding Partner.
- The On-boarding Partner Portal, directly accessible from the [EMVO Website](#).
- The On-boarding [Presentation](#) and [Guidelines](#).
- The On-boarding Partner Portal [Training Video](#).
- The EMVO [Knowledge Database](#).
- The National Medicines Verification Organisations' (NMVOs) contact information, available on the [EMVO Website](#).

In order to communicate this important note to the most appropriate audience in your company, EMVO would kindly request your support and ask you to transfer this letter to your relevant internal department. In the event of any question or uncertainty, please do not hesitate to contact the EMVO Helpdesk:

Tel. Helpdesk: +372 611 90 44

E-Mail: helpdesk@emvo-medicines.eu

EMVO Team
European Medicines Verification Organisation
www.emvo-medicines.eu